Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Price Target at $129.56

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the nineteen analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $129.5625.

Several equities research analysts have recently weighed in on BNTX shares. Truist Financial raised BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research note on Friday. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. Wells Fargo & Company reduced their price objective on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Morgan Stanley upped their price objective on shares of BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, April 10th.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at $44,156,226.72. The trade was a 11.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by company insiders.

Institutional Trading of BioNTech

Large investors have recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA raised its stake in BioNTech by 41.6% during the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company’s stock valued at $8,457,000 after purchasing an additional 26,119 shares during the period. Long Focus Capital Management LLC raised its stake in BioNTech by 91.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 397,655 shares of the company’s stock valued at $39,217,000 after purchasing an additional 189,752 shares during the period. LBP AM SA raised its stake in BioNTech by 4.3% during the 4th quarter. LBP AM SA now owns 368,584 shares of the company’s stock valued at $35,089,000 after purchasing an additional 15,255 shares during the period. Hudson Bay Capital Management LP raised its stake in BioNTech by 36.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company’s stock valued at $20,217,000 after purchasing an additional 55,004 shares during the period. Finally, Victory Capital Management Inc. raised its stake in BioNTech by 97.0% during the 3rd quarter. Victory Capital Management Inc. now owns 413,685 shares of the company’s stock valued at $37,531,000 after purchasing an additional 203,700 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Down 1.7%

Shares of BNTX stock opened at $88.08 on Friday. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market cap of $22.27 billion, a PE ratio of -14.98 and a beta of 1.32. The business’s fifty day moving average is $94.54 and its 200-day moving average is $98.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. Equities analysts expect that BioNTech will post -4.66 earnings per share for the current fiscal year.

BioNTech announced that its board has approved a share repurchase plan on Thursday, May 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.